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Introduction
The dangers of bioterror bacterial or viral agents have been of concern to the military and political leaders for decades. Methods to prevent infection with these agents and to treat infections that may occur are being studied with intensity. Historically, vaccines have been the most efficient method of handling diseases in large populations.
Studies of the immune system and vaccine effectiveness have shown that the ideal way to induce a complete immune response of both the mucosal and systemic systems is to administer vaccines in a manner that mimics the natural route of infections. Over the past 15 years, experimental bacterial vaccine vectors have been produced that elicit immune responses against bacterial, viral, protozoan and metazoan pathogens in laboratory animals.
Among the advantages of these vaccines is that they are relatively inexpensive to manufacture, they can be given orally, and they can be treated with antibiotics if desired and they effectively induce both humoral and cellular responses. If the organism used as the vector can potentially colonize in the host, the potential of eliciting the appropriate response is increased.
OmpA proteins are among the most conserved of all outer membrane proteins in bacteria; however, the loops expressed on the outer surface are quite variable. Current understanding indicates that the loops are responsible for a variety of virulence characteristics and that they serve as important antigens as well. Bacteroides fragilis, most common anaerobic pathogen, is a major component of the stool flora and colonizes the gastrointestinal tract. OmpA is one of the major outer membrane proteins of this organism.
Structure/function analysis of the OmpA protein, which will ultimately identify the exposed loops of the protein will both elucidate the role of OmpA in the pathogenic process of Bacteroides fragilis and will allow us to exploit the unique nature of this abundant outer membrane protein in designing potential vaccine vectors. These vaccines (i.e., Bacteroides fragilis with OmpA modified to express specific epitopes) could be designed for a wide variety of infections that might be acquired by ingestion of food or liquid (including potential biodefense related organisms), and the secretory IgA antibodies produced in the gastrointestinal tract could prevent the pathogen or toxin from exiting the GI tract to invade the circulatory system or other organs.
BODY:
We have made significant and timely progress in the proposed grant. The progress and accomplishments for each Task during the past year is indicated ♦ ♦ ♦ ♦Task 1: Construct and characterize an ompA deletion mutant Task 1a: Construction of the ompA deletion mutant. √ √ √ √ Completed in Phase 1.
Task 1b: Characterize the deletant strain.
Characterization of the ompA deletion mutant. In Phase 1, we demonstrated that the WAL 186 ompA deletion mutant was more sensitive to SDS and high salt concentration.
Furthermore, both the WAL 108 parental strain and the WAL 186 deletant had small round forms when grown on hyperosmolar media. We also found that while all four ompA homologs were transcribed in the parental strain, ompA4 was not transcribed (nor, obviously ompA1) in the deletant strain, indicated that there was negative regulation involved. Strain 186 (ompA deletant) is being further characterized by transcriptome analysis (see Task 1d). We had not expected that a thy mutation would have this effect. In order to more closely examine the differences that the thy disruption is creating in WAL 108 (since this will be the basic strain for our vaccine vector, we have prepared a cDNA library from RNA from the type strain, 638R (parental strain for WAL 108), WAL 108 (the thystrain used to construct the deletion mutant), WAL 186 (the ompA deletant), and WAL 361 (the strain in which the recombinant ompA was inserted back into the chromosome). We submitted these strains for microarray analysis to Nimblegen and expect the results by the end of April 2008. These results will be important in assessing the utility of this strain as the carrier for the vaccine vector. Current status: We successfully cloned the OmpA gene into the pet27b vector as indicated in the Report of January 2007. We then needed to express this gene so that it could be properly exported to the outer membrane. We repeatedly tried various permutations in order to express the ompA gene in E. coli, but found that the protein expression was toxic to the cells. Although we were able to obtain constructs in which the ompA gene was expressed, these clones were unstable. Thus, these experiments have "morphed" into Task 4, and we are using allelic exchange to insert the modified ompA genes directly into the chromosome of the ompA deletant of B. fragilis. Thus, the modified gene will be in exactly the position as the original gene, and will be under the same regulatory controls as the original gene. Current status: We decided that it would be very useful to have restriction sites "bracketing" the loop regions of the genes. There were no restriction sites unique to the gene (and not present on the plasmid) in the appropriate positions. Therefore, we planned to insert two restriction sites (AatII and SalI) at the appropriate sites on the ompA genewithin loop 2 and one within loop 3. This will allow us to insert the desired epitopes either in Loop 2 or Loop 3 and determine which is the more advantageous. However, the suicide vector, pADB242a, did have one AatII restriction site. Thus, we had to remove this site from the pADB242a vector so that we could then use the vector for further manipulation with the two restriction enzymes. We accomplished this using the NEB Quick blunting kit, creating pADB242amod.
Construction of OmpA-AatII (OmpA R99DVG100 ). We PCR amplified the gene from the beginning of the upstream site (~800 bp upstream of the ompA gene) until the beginning of Loop 2 (R 99 ), adding an AatII site to the reverse primer. At the same time, the downstream portion of the insert (beginning at G 100 and ending ~800 bp after the end of the ompA gene) was PCR amplified, with an Aat II site added to the forward primer.
The PCR products were respectively cloned into the TOPO TA cloning vector (Invitrogen) and E. coli Top 10 was transformed (separately) with the products. Potential clones were verified with PCR and restriction analysis. The two TOPO constructs (TOPO::
(HindIII)ompAup-ompA R99 (AatII) and TOPO::(AatII)ompA G100 -ompAdown(BamH1)
were digested, respectively, with HindIII/AatII and BamH1/AatII. The ompA inserts were gel purified and used in a three part ligation with a) pBR322 and b) pADB242amod that had been digested with BamH1 and HindIII. Potential ligated plasmids were used to electroporate electrocompetenet E. coli XL Gold supercompetent cells. We obtained positive transformants only with the pBR322 plasmid (we had originally included this plasmid since it is smaller and transforms more easily than pADB242amod.) Positive transformants were identified by restriction analysis and submitted for sequencing. After confirmation of the correct insert, it will be cut out of pBR322 and inserted into similarly digested pADB242Amod, and used for the two part recombination into B. fragilis in Task 4b.
Future modification of the vector ompA insert. The next step will be to construct modified ompA genes with both restriction sites (Aat II in Loop 2 (the longest loop and that most likely to carry the desired epitope) and SalI in loop 3.) Using this modified construct, we will be able to prepare plasmid containing this modified OmpA and digest with AatII and Sal I. The linearized plasmid will then be used in a ligation with a PCR product We have modified our plan for constructing these strains. We are now using our ompA deletant strain, constructed during the first phase of these studies, as the parental strain. Using the same two step recombination procedure that was used to construct that strain, we will replace the missing gene with a modified ompA gene. This technique has several advantages over gene replacement: After the two step recombination, the only strains with an OmpA protein will have the modified OmpA protein, since we are beginning with a strain lacking this protein. This two step recombination procedure involves a plasmid containing the modified gene, flanked by approximately 800 bp upstream and downstream sequences, consecutively. After the cointegration and second step recombination, we will be left with either parental strain (ie. ompA deletant) or strains carrying the modified ompA.
To confirm that this plan will work properly, we first reinserted the recombinant, DNA sequencing and confirmed no sequence differences between the parent strain and the deletant strain in which the ompA gene was reinserted. We analyzed the outer membrane protein profile of this strain by SDS-PAGE analysis and confirmed that the OmpA protein is indeed translated.
Crude outer-membranes of the wild type, ompA1 deletant and ompA1 restored strains were analyzed by SDS-PAGE (below). This confirmed that the heat-modifiable
OmpA1 was present in the restored strain, demonstrating that our method for genetically manipulating B. fragilis to delete and reinsert the ompA1 gene did not affect its translation.
This method will be adapted to introduce recombinant ompAs into B. fragilis to study their immunogenic properties. epitope displayed in OmpA will be detected by Whole-cell ELISA using monoclonal M2 antibody for FLAG and Proteoqwest Kit (Sigma).
Optimizing electroporation for transforming B. fragilis. We are optimizing electroporation as an efficient method to introduce the suicide vector into B. fragilis.
Electroporation has not been used at all for Bacteroides, and thus we are limited to the three part mating technique, which we have used successfully for many allelic exchanges, including the replacement of the ompA gene in the deletion mutant. We are intensively investigating methods of electroporation used for a wide variety of microorganisms. If we are successful at optimizing the electroporation protocol, the time for producing the appropriate strains of B. fragilis with modified ompA genes for biodefense vaccines can be reduced from a matter of weeks to a matter of days. A successful protocol will not only be very useful for us, but for all of the investigators doing gene manipulation in B. fragilis.
We hope that we will be able to optimize this procedure within the next few months.
However, if we are not successful, we will still be able to complete all of the experiments using the three part mating protocol as we are originally proposed.
Task 4c. Confirm that modified loops are exposed in allele-exchanged B.
fragilis.
Current status: These experiments will commence as soon as Task 4b has been
completed. We anticipate that Task 4b will be completed with four months, and once begun, task 4c should be completed within three to six months (i.e., within ten months from now.) were deficient in 1) adherence to intestinal epithelial cells and 2) biofilm formation compared to strain 638R (WAL 108 is a thydeficient mutant of 638R, engineered to be more amenable to use in allelic exchange experiments) (Task 1D), there was no further need to test specific loop deletants. 
Introduction
Porphyromonas asaccharolytica is a Gram-negative non-sporulating anaerobic rod which was formerly part of the genus Bacteroides [1] . Infections by this pathogen are associated with soft tissue infections below the waist, foot ulcers, appendiceal abscesses and empyema [2] . P. asaccharolytica was also implicated in cases of bacteremia [3] and in a left cardiac myxoma [4] . Bacteroides fragilis, a non-spore-forming, Gram-negative rod, is OmpA in the pathogenic process has been increasingly recognized. OmpA has been implicated in the invasion of brain microvascular endothelial cells (BMEC) [6, 7] and has been shown to contribute to the ability of E. coli to cross the blood-brain barrier [8] .
Outer membrane proteins of the porin class, in general, possess a variety of immunomodulatory and procoagulant activities [9] [10] [11] [12] . Omp-PA of P. asaccharolytica is the major porin protein of that organism [13] . In contrast, the Bf-OmpA protein does possess some pore-forming activity in liposomes but is not the major porin protein of B.
fragilis [14] . Non-toxic concentrations of porins from a variety of organisms stimulate the synthesis and release of platelet-activating factor and promote proinflammatory and immunomodulatory cytokine release from immunocompetent cells or other cellular sources [15] . Porins can induce the release of TNF-α, IL-1α, and IL-6 by human monocytes and of IFN-γ and IL-4 by human lymphocytes. This was seen with porins from Salmonella typhimurium [11, 16, 17] , Pseudomonas aeruginosa [10, 15] , and Pasteurella multocida [12] .
The OmpA-like porin from Acinetobacter spp. stimulates the secretion of gastrin and IL-8 [18] , and Shigella dysenteriae type 1 porin induces the release of nitric oxide and IL-1 [9] .
The accumulated evidence clearly indicates that porins mediate release of cytokines and other proinflammatory factors, and that this activity may vary from one porin type to another.
The aim of this study was to investigate and compare the abilities of the OmpA proteins P. asaccharolitica and B. fragilis to induce the release of different cytokines by murine splenocytes in vitro. The significance of this study is due to the fact that Bacteroides and anaerobes in general are quite different from other aerobic microorganisms.
Materials and methods

Animals
BALB/cByJ male mice 8 weeks old were used. The animals were housed at constant temperature (20 ± 2°C) under a fixed 12 h light-dark cycle with free access to food and water. [19] and was 10 pg/10 µg porins. To eliminate any biological effect of LPS, proteins were incubated for 1 h with 5 µg/ml polymyxin B (Sigma) at room temperature [20] . In all of the tests performed, the porin with polymyxin B gave the same results as the porin alone (data not shown).
Preparation of
SDS polyacrylamide gel electrophoresis
The supernatant containing the OmpA protein was subjected to SDS-PAGE in a modified Laemmli gel with an acrylamide:bisacrylamide ratio of 30:0.8 and an acrylamide concentration of 12.5% w/v for the running gel and 5% w/v for the stacking gel. Molecular weights were determined using molecular weight standard proteins (#161-0304, BioRad).
Passive elution
Bands corresponding to Omp-PA (37 kDa) and Bf-OmpA (36.8 kDa) were cut out from the gel, placed in dialysis bags and mashed manually. Buffer containing 25 mM Tris, 192 mM glycine, 0.1% SDS, and 3 mM sodium azide was then added and the preparations were dialyzed against the same buffer overnight at 4 ºC. The gel/buffer mixtures were centrifuged to remove the gel traces, which were re-extracted with the same buffer and recentrifuged. In order to remove the detergent traces the supernatants from both extractions were combined and redialyzed against buffer containing 20 mM Tris-HCL and 3 mM sodium azide for 4 days at room temperature, with frequent changes of the buffer, and then lyophilized. 
Refolding of over-expressed Bf-OmpA
The frozen inclusion bodies were resuspended to 20 mg/mL (0.48 mM) in 8 M urea, 10 mM borate, 2 mM EDTA, pH 10. Twelve milligrams of the resuspended protein was incubated with 16 mM 3-14 zwittergent for 4 days at 37ºC. A band indicating the refolded Bf-OmpA was cut out of the gel, passively eluted, and then diluted in the cell culture at the appropriate concentration (0.1±10 mg ml -1 ) for the cytokine assays.
Murine splenocyte preparation
Murine splenocytes were prepared according to conventional procedures from aseptically removed mouse spleens (known to contain more than 97% lymphocytes of different types). Erythrocytes were lysed using 0.155 M NH 4 Cl, washed three times in RPMI 1640 medium (Labtek Laboratories, Eurobio, Paris, France), resuspended in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), glutamine (2 mM), penicillin (100 U ml -1 ), and streptomycin (100 U ml -1 ) at a concentration of 3 x 10 6 cells ml -1 , and incubated at 37 °C in a humidified atmosphere containing 5% CO 2 .
Murine splenocyte stimulation
Murine splenocytes resuspended at 3 x 10 6 cells ml -1 in complete medium were divided into aliquots to be treated or left untreated. The proteins were prepared in pyrogenfree distilled water and then diluted in the cell culture at the appropriate concentration (0.1±10 µg ml -1 ). The incubation time was 24 h and 48 h for cytokine assays and 3 h for mRNA analysis.
Cytokine assays
All assays were carried out with 3 x 10 6 cells ml-1 stimulated with various concentrations of Omp-PA, native Bf-OmpA, and recombinant Bf-OmpA, and were incubated at 37 °C in 5% CO 2 for 24 and 48 h. At specified time intervals, cell viability was checked by Trypan blue exclusion test. Culture supernatants were harvested by centrifugation and stored at antibodies. IL-1α, IL-6, TNF-α, IFN-γ, and IL-10 were measured by immunoenzymatic methods (ELISA kits of Invitrogen, Biosource, Worcester, MA).
Lactate dehydrogenase (LDH) assay
LDH assay was carried out according to the manufacturer's instructions using a Cytotoxicity Detection kit (Promega). LDH is a stable cytoplasmic enzyme present in all cells and is rapidly released into cell culture supernatant upon damage of the plasma membrane. LDH activity was determined by a coupled enzymatic reaction whereby the tetrazolium salt (INT) was reduced to formazan. An increase in the number of dead or damaged cells results in an increase in LDH activity in the culture supernatant.
R A isolation and cD A preparation
The concentrations of Omp-PA used in the assay were 0.1 µg/ml for TNF-α, 1 µg/ml for IFN-γ and IL-10, and 5 µg/ml for IL-1α and IL-6. The concentrations of native and recombinant Bf-OmpAs used in the assay were 0.1 µg/ml for IL-1α and IFN-γ, 1 µg/ml for TNF-α, and 5 µg/ml for IL-6. Non-stimulated cells were used as negative controls. The stimulated and the non-stimulated cells were collected after 3 h of incubation. Mouse βactin was used as an internal standard. Total RNA was extracted according to the method of Chomczynski and Sacchi [21] . The RNA pellet was resuspended in 75% ethanol, sedimented, vacuum-dried and dissolved in 50 µl of RNase free water. One µl of oligo (dT) (Promega Biotechnology, Madison, WI) was added to the suspension containing 2 µg of RNA and the mixture was heated at 70 °C for 5 min. After cooling on ice, the mixture was 
PCR procedure
The primer pair sequences were designed on the basis of published cytokine gene sequences as reported in Table 2 . The primer sequences were complementary to sequences in the exons or spanned exon ± exon junctions and thus were RNA-specific. One µl of cDNA prepared as described above was amplified in the presence of 1 µl of 5 
Statistics
The immunoenzymatic assays were carried out in triplicate and the results were expressed as the mean ± standard deviation. Comparisons between tests were made by Student's t-test with statistical significance considered to be p<0.05.
Results
Purity of Omp-PA and Bf-OmpA preparations
SDS-PAGE analysis of the purified proteins is shown in Fig. 1 .
SDS-PAGE of
Omp-PA showed one band with a molecular weight of 37 kDa (Lane 3, Fig. 1 ), as reported previously [13] . SDS-PAGE analysis of Bf-OmpA demonstrated one band of 36.8 kDa (Lane 4, Fig. 1 ), as previously reported [14] . The Limulus test indicated that LPS Approximately 51% of the overexpressed protein could be refolded under these conditions.
The refolded Bf-OmpA migrated at the same apparent molecular weight of 36.8 kDa as the native Bf-OmpA (Fig. 2) . It was shown earlier that the refolded Bf-OmpA has similar activity to the native protein in the liposome assay [14] . Fig. 3 . The highest levels of the cytokine secretion were observed with the Omp-PA concentrations of 0.1 µg/ml for TNF-α, 1 µg/ml for IFN-γ and IL-10, and 5 µg/ml for IL-1α and IL-6. Concentrations higher than those caused a decrease in cytokine production, and a concentration lower than 0.1 µg/ml showed no significant effect. Both native and refolded recombinant Bf-OmpAs were able to regulate release of IL-1α, TNF-α, IFN-γ, and IL-6 but in much lower levels compared to those obtained using Omp-PA. Both native and recombinant Bf-OmpAs had no significant effect on the release of IL-10 under the same experimental conditions. The highest levels of the cytokine secretion were observed with the protein concentrations of 0.1 µg/ml for IL-1α and IFN-γ, 1 µg/ml for TNF-α, and 5 µg/ml for IL-6. concentrations that showed maximum release of each cytokine as measured by ELISA kits (Fig. 3) . The mRNA levels of all five cytokines, IL-1α, TNF-α, IFN-γ, IL-6, and IL-10,
Cytokine mR
were increased upon stimulation of the cells by adding appropriate concentrations of Omp-PA (Fig. 4) . The mRNA levels of the cytokines IL-1α, TNF-α, IFN-γ, and IL-6, expressed by stimulation of the cells with native and recombinant Bf-OmpAs, were similarly increased, but were found to be lower compared to those expressed by Omp-PA. Very low expression of IL-10 mRNA was detected under the same experimental conditions. The non-stimulated cells did not show increased mRNA expression of the tested cytokines ( Fig. 4 ).
Discussion
In this study, we investigated the ability of the OmpA proteins from P.
asaccharolytica and B. fragilis to trigger release and expression of proinflammatory and immunoregulatory cytokines IL-1α, TNF-α, IFN-γ, IL-6, and IL-10 by murine splenocytes in vitro. Both native and refolded recombinant B. fragilis Bf-OmpA which are proved to be functionally identical [14] could elicit the cytokine release, but we were not able to refold the Omp-PA, and therefore, could not test it in this assay. The main reason for using recombinant refolded Bf-OmpA was to avoid the possibility that any capsule contamination in the purified protein preparation may be responsible for the cytokine production [5] . The cytokine release proceeded in a dose-dependent fashion with different concentrations of porins needed for the maximum release of each cytokine. The release of IL-1α and IL-6 stimulated by Omp-PA was relatively low compared to the high-level production of TNF-α, IFN-γ, and IL-10. The results obtained cannot be attributed to the contaminating LPS (10 pg/10 µg of porin) in the porin preparations, because this trace amount of LPS had no ability to induce any cytokine production (data not shown).
Moreover, porins were incubated with polymyxin B to neutralize biological activity of lipid A [16] . It is proved that the porin-polymyxin complex has the same activity in the induction of the cytokine secretion as the porin preparations alone, while the LPSpolymyxin complex is inactive [17] .
Interestingly, Omp-PA was able to induce cytokine release at much higher levels compared to those obtained with native and recombinant Bf-OmpAs. We were initially surprised by this because P. asaccharolytica is considered to be less pathogenic than B. fragilis. However, mice were used as the experimental animals, and B. fragilis is part of mouse intestinal microflora. Thus the mouse was potentially immunized to the Bf-OmpA [22] , which may explain why the stimulation of murine splenocytes by B. fragilis porin did not result in high-level secretion of cytokines.
Alternatively, perhaps other porin proteins present on the B. fragilis outer membrane may have more cytokine-stimulating activity. For example, the B. fragilis Omp-200 has more pore-forming activity than OmpA [23] . On the other hand, only one active monomeric porin (Omp-PA) was isolated from the outer membrane of P. asaccharolytica.
As expected, exposure to Omp-PA and native and recombinant Bf-Omp resulted in increased levels of IL-1α, TNF-α, IFN-γ, IL-6, and IL-10 mRNA expression. Results obtained in RT-PCR analysis corresponded to those measured by ELISA kits. For comparison purposes, we also checked the ability of another outer-membrane protein,
Omp-EA, to induce the release and expression of IL-6 and IFN-γ. Omp-EA is an outer membrane protein from Erwinia amylovora, a pathogen which infects only plants [24] . As expected, Omp-EA acted as a negative control and did not induce release of the tested cytokines (data not shown).
Recent reports suggest that the ability to induce cytokine production by the porins is dependent on the existence of the externally exposed loops that have been described extensively [25] . We have recently described these loops in monomeric porins from
Acinetobacter baumannii [26] , B. fragilis [14] , and P. asaccharolytica [13] . Future work will include studying the role of the external loops of P. asaccharolytica
Omp-PA and B. fragilis Bf-OmpA in induction of cytokine release. Table 1 .
Primers used for the pET cloning
Primer sequence (5` to 3`)
OmpAfwd TGTTCATATGCAGCAGACTACAATTACGGGAT OmpArev AAGTGGATCCTTATTTAACAGACTCTACTAATA Table 2 Primer sequences used for RT-PCR
Cytokine
Oligonocleotide sequence IL-1α 5`AAGATGTCCAACTTCACCTTCAAGGAGAGCCG3` 5`AGGTCGGTCTCACTACCTGTGATGAGTTTTGG3`
T F-α 5`TTCTGTCTACTGAACTTCGGGGTGATCGGTCC3` 5`GTATGAGATAGCAAATCGGCTGACGGTGTGGG3`
IF -γ 5`TGCATCTTGGCTTTGCAGCTCTTCCTCATGGC3` 5`TGGACCTGTGGGTTGTTGACCTCAAACTTGGC3` IL-6 5`ATGAAGTTCCTCTCTGCAAGAGACT3` 5`CACTAGGTTTGCCGAGTAGATCTC3` IL-10 5`CTGGAAGACCAAGGTGTCTAC3` 5`GAGCTGCTGCAGGAATGATGA3` β-actin 5`GTGGGCCGCTCTAGGCACCAA3` 5`CTCTTTGATGTCACGCACGATTTC3` 
Figure legends
